Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Ambient AI Documentation in Oncology Consultations (NVC-AI-DOC)

Feasibility Study of Ambient Artificial Intelligence Documentation Systems for Oncology Consultations at the National Cancer Center

This study tests whether an artificial intelligence (AI) system can help doctors write medical notes during cancer consultations.

After a cancer patient is seen by a multidisciplinary team (a group of specialists who decide on the best treatment), they have a consultation with their oncologist to discuss the treatment plan. During this consultation, doctors must write detailed medical notes, which takes significant time and effort.

In this study, an ambient AI system called VOCALI is used during oncology consultations at the National Cancer Center in Vilnius, Lithuania. Before the consultation begins, the doctor loads relevant pseudonymized clinical data from the electronic health record (such as diagnosis and treatment plan) into the system. During the consultation, VOCALI records the conversation (with the patient's consent) and combines it with the loaded clinical data to automatically generate a draft medical note in Lithuanian. Patients may ask the doctor to stop the recording at any time. The doctor then reviews the draft, makes any necessary corrections, and approves the final document. The AI does not make any medical decisions - the doctor is always responsible for the final note.

What the study measures:

The study has three main goals:

  • To assess the quality of the AI-generated notes, rated by two independent reviewers using the PDQI-10, a standardized documentation quality instrument translated into Lithuanian using forward-backward translation
  • To measure the time doctors spend reviewing and approving the AI-generated draft
  • To monitor safety - whether any AI errors could affect patient care

The study also collects information on doctor workload, ease of use of the system, and patient satisfaction with the consultation.

Who can participate:

Adult patients (age 18 or older) attending a primary oncology consultation at the National Cancer Center in Vilnius, Lithuania, after a multidisciplinary team decision, who speak Lithuanian and provide written consent.

Study details:

250 patients will be enrolled over 12 months. Each participant attends one consultation and completes a short satisfaction questionnaire (about 5 minutes). No additional visits are required. There is no comparator group - all participants receive the AI-assisted documentation.

This is the first study to evaluate ambient AI documentation in the Lithuanian language and in the Lithuanian oncology setting.

Panoramica dello studio

Descrizione dettagliata

BACKGROUND Electronic health record (EHR) documentation imposes a substantial administrative burden on physicians and is a major contributor to professional burnout. Studies consistently show that clinicians spend up to half their working time on computer-based documentation, leaving less than 30% of the working day for direct patient contact. Ambient AI documentation systems have shown reductions in documentation time and cognitive load across multiple health systems in the United States and Europe, with AI-generated note quality approximating that of physician-authored notes as measured by a modified Physician Documentation Quality Instrument (PDQI-9). No studies have evaluated ambient AI documentation in the Lithuanian language or in the Lithuanian oncology setting.

STUDY DESIGN Prospective, single-group, single-center feasibility study conducted at the National Cancer Center (NVC), Vilnius, Lithuania. No randomization or control arm.

AI DOCUMENTATION SYSTEM The VOCALI ambient AI system is activated at the start of each eligible consultation. Before the consultation, the physician loads pseudonymized clinical data from the EHR (diagnosis, MDT decision, treatment plan) into the system. The system audio-records the consultation in real time, integrates the preloaded clinical data, and generates a structured draft of the E025 outpatient clinical note in Lithuanian. The physician reviews, edits if necessary, and approves the final document in the EHR. The system does not make autonomous clinical decisions.

PROCEDURES

  • Informed consent obtained before consultation, including consent to audio recording.
  • PSQ-18 patient satisfaction questionnaire completed by participants on the same day post-consultation (~5 min).
  • PDQI-10 documentation quality instrument rated by two independent raters per AI-generated note.
  • NASA-TLX physician workload questionnaire administered at baseline (T0), 1 month (T1), and end of enrollment (T2).
  • SUS system usability scale completed by physicians at T2.
  • Documentation time and draft editing extent (% characters changed) logged automatically by the system.
  • Safety incidents reported by physicians within 3 working days; monthly safety review meeting held; immediate notification of the NVC Deputy Director for Medicine and the ethics committee required for level-5 (critical) incidents.

SAMPLE SIZE 250 participants will be enrolled over a 12-month period. As a feasibility study, sample size was determined by practical feasibility and literature precedent rather than formal power calculation. With n = 250, proportions can be estimated with a 95% CI of approximately ±3-4%; if no critical incident is observed, the upper 95% confidence limit is 1.2% (rule of three). Approximately 20% data loss is anticipated.

STATISTICAL ANALYSIS R ≥4.0 or SAS ≥9.4. Descriptive statistics for all outcomes. PDQI-10 mean score with 95% CI and domain-level analysis; documentation time as mean with 95% CI and median with IQR; SUS mean with 95% CI; PSQ-18 subscale means. Inter-rater reliability assessed by rWG coefficient (target ≥0.7). Critical incident rate reported with 95% CI using the Clopper-Pearson method. NASA-TLX change (T2-T0) analyzed by paired t-test or Wilcoxon signed-rank test depending on distribution. All inferential tests are descriptive in intent; results interpreted via confidence intervals.

DATA PROTECTION All participant data are pseudonymized immediately upon enrollment. Audio recordings and transcripts are stored in the VOCALI provider's secure infrastructure under a data processing agreement per GDPR Article 28; the provider has no access to identifiable participant data. Data retained for 5 years after study completion.

Tipo di studio

Osservativo

Iscrizione (Stimato)

250

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Vilnius City
      • Vilnius, Vilnius City, Lituania, LT-08660
        • National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
        • Contatto:
        • Investigatore principale:
          • Ernestas Sileika, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Adult oncology patients attending a primary oncologist consultation at the National Cancer Center (Vilnius, Lithuania) following a multidisciplinary team (MDT) decision, with diagnosis and treatment plan established.

Descrizione

Inclusion Criteria:

  • Age 18 years or older at the time of signing the informed consent form
  • Primary oncologist consultation at the National Cancer Center following a multidisciplinary team (MDT) decision, with diagnosis and treatment plan established at the MDT meeting
  • MDT protocol available in the electronic health record (EHR)
  • Signed informed consent form, including consent to audio recording of the consultation

Exclusion Criteria:

  • Absence of MDT protocol in the EHR
  • Diagnosis or treatment plan not yet established
  • MDT recommended additional diagnostic workup (treatment plan not yet defined)
  • Palliative care consultation (not active oncological treatment planning)
  • Non-Lithuanian speaking patients
  • Cognitive impairment affecting ability to understand study information
  • Hearing impairment affecting participation in verbal consultation

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Oncology patients undergoing AI-assisted consultation

Adult oncology patients attending a primary oncologist consultation at the National Cancer Center following a multidisciplinary team (MDT) decision, during which the VOCALI ambient AI documentation system is used to generate a draft clinical note (E025 form).

An ambient artificial intelligence documentation system that records the consultation audio, integrates relevant pseudonymized clinical data from the electronic health record (EHR), generates a speech transcript, and produces a draft clinical note (E025 form) for physician review and approval. The system does not make autonomous clinical decisions. The physician reviews, edits if necessary, and approves all AI-generated content before it is saved to the EHR.

Altri nomi:
  • VOCALI

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Documentation Quality - AI-Generated Clinical Documentation Quality (PDQI-10)
Lasso di tempo: Per consultation, throughout the enrollment period (up to 12 months)

Mean score assessed by two independent raters using the Physician Documentation Quality Instrument (PDQI-10), covering 10 domains (accuracy, completeness, usefulness, organization, clarity, conciseness, synthesis, consistency, data accuracy, and bias) on a 1-5 Likert scale.

Per consultation, throughout the enrollment period (up to 12 months)
Documentation Efficiency - Documentation Completion Time
Lasso di tempo: Per consultation, throughout the enrollment period (up to 12 months)

Time (in minutes) from opening the AI-generated draft to final approval in the electronic health record (EHR), automatically recorded by the system.

Per consultation, throughout the enrollment period (up to 12 months)
Safety - AI System Incident Rate
Lasso di tempo: Per consultation, throughout the enrollment period (up to 12 months)

Frequency of AI documentation incidents classified by a 5-level severity scale (1 = insignificant, 2 = minor, 3 = moderate, 4 = major, 5 = critical). Incidents reported by physicians within 3 working days. Critical incident (level 5) rate reported with 95% confidence interval using the Clopper-Pearson method.

Per consultation, throughout the enrollment period (up to 12 months)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Physician Subjective Workload (NASA-TLX)
Lasso di tempo: Baseline (T0), 1 month (T1), and end of enrollment period (T2, up to 12 months)

Physician-reported workload assessed using the NASA Task Load Index (NASA-TLX), covering 6 dimensions (mental demand, physical demand, temporal demand, performance, effort, frustration). Change from baseline (T0) to end of enrollment (T2) analyzed by paired t-test or Wilcoxon signed-rank test.

Baseline (T0), 1 month (T1), and end of enrollment period (T2, up to 12 months)
System Usability (SUS)
Lasso di tempo: End of enrollment period (T2, up to 12 months)

Physician-rated system usability assessed using the System Usability Scale (SUS), a 10-item questionnaire scored 0-100.

End of enrollment period (T2, up to 12 months)
AI Draft Editing Extent
Lasso di tempo: Per consultation, throughout the enrollment period (up to 12 months)

Proportion of characters modified between the AI-generated draft and the final approved document, expressed as percentage. Automatically calculated per consultation.

Per consultation, throughout the enrollment period (up to 12 months)
Patient Satisfaction with Consultation (PSQ-18)
Lasso di tempo: After each consultation, throughout the enrollment period (up to 12 months)

Patient-reported satisfaction assessed using the Patient Satisfaction Questionnaire (PSQ-18), an 18-item instrument. Results reported as subscale means.

After each consultation, throughout the enrollment period (up to 12 months)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Investigatore principale: Ernestas Šileika, National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 novembre 2027

Completamento dello studio (Stimato)

31 dicembre 2027

Date di iscrizione allo studio

Primo inviato

23 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

23 settembre 2026

Primo Inserito (Effettivo)

30 settembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

30 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • NVC-2026-001
  • 2026/5-1769-1212 (Altro identificatore: Vilnius Regional Biomedical Research Ethics Committee)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared. The ethics-approved protocol and the informed consent do not provide for transfer of individual data to third parties, in accordance with the EU General Data Protection Regulation (GDPR) 2016/679 and Lithuanian data protection legislation. The data include consultation audio recordings and clinical documentation. Only aggregated results will be published in scientific journals and presented at conferences.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi